Trigger-based adaptive proton therapy improves coverage and cardiac sparing in esophageal cancer
Adaptive IMPT improved cumulative target coverage and reduced heart dose without increasing lung dose in a 192-patient retrospective cohort.
Tag
esophageal
PET/CT reshaped esophageal radiotherapy targets and reduced lung dose
PET/CT reduced mean PTV by 149 cm³ while identifying substantial disease outside CT-based targets in 20% of patients.
Adaptive IMPT preserved gross tumor dose despite frequent ITV undercoverage in esophageal cancer
ITV underdosage occurred in 21% of distal esophageal IMPT patients, yet no GTV underdosage occurred and tumor response was unchanged.
Heart-base optimization substantially reduced cardiac substructure dose in distal esophageal RT
Heart-base-optimized IMRT/VMAT reduced cardiac avoidance area mean dose by about 6 Gy without compromising target coverage.
ICI timing did not change pathological response when neoadjuvant ESCC backbones were matched
Concurrent and consolidation ICI produced similar pathological response rates once analyses were restricted to neoadjuvant chemoradiotherapy studies.
Higher radiotherapy dose tracked with greater pathological response in neoadjuvant esophageal chemoradiotherapy
Each 10-Gy increase in biologically effective dose was associated with 39% higher odds of pathological complete response in esophageal squamous cell carcinoma.
Cardiac avoidance area dose was associated with survival after oesophageal radiotherapy
Maximum cardiac avoidance area dose below 43.5 Gy was associated with longer median survival after curative-intent oesophageal radiotherapy.
NRF2-WNT5A signaling promoted stemness and radioresistance in esophageal squamous cancer
NRF2 directly activated WNT5A, sustaining β-catenin signaling, cancer stemness and radioresistance across esophageal cancer models.
Age and comorbidity identified poor prognosis in elderly patients receiving esophageal chemoradiotherapy
Patients aged ≥75 years with CIRS-G ≥7 had median overall survival of 16 months after definitive chemoradiotherapy.
Esophageal radiosensitization has many molecular targets but little practice-ready clinical evidence
A broad 6R-based review identifies numerous radiosensitization targets, but most remain preclinical and evidence is heavily concentrated in squamous-cell carcinoma.
Three clinical variables predicted moderate-to-severe esophagitis during esophageal cancer radiotherapy
Tumor location, hypertension and albumin predicted moderate-to-severe acute esophagitis with an internally validated AUC of 0.816.
Heart dose rises during esophageal IMPT but adaptive replanning limits the increase
Mean heart dose increased during esophageal IMPT, while heart-dose–triggered replanning reduced the excess dose in patients requiring adaptation.
Chemoradiotherapy and immunoradiotherapy reshape distinct esophageal cancer microenvironment programs
Chemoradiotherapy suppressed LAMC2–macrophage signalling, while immunoradiotherapy enriched CCL5-positive CD8 T cells in preclinical esophageal squamous-cell carcinoma models.
Escalating esophageal chemoradiotherapy from 50.4 to 60 Gy provided no benefit
Three-year outcomes numerically favored 50.4 Gy over 60 Gy, while multivariable analysis found no significant survival advantage from either dose.
Tetrandrine trial will test prevention of lung injury during esophageal chemoradiotherapy
A randomized phase II trial will test whether intravenous tetrandrine reduces grade 2 or higher lung injury from 25% to 10%.